Last mentioned: Mar 26, 2026
Current Data Release
National reports show abortion numbers holding steady despite 14+ state bans.
Framework Release
White House unveils the final Comprehensive AI Governance Framework for high-stakes sectors.
Public Disclosure
Stryker flags significant disruption to orders and manufacturing in regulatory filings and public statements.
Attribution
Security researchers and the group Handala link the attack to Iranian-backed cyber operations.
Breach Detected
Stryker identifies a sophisticated intrusion into its Windows-based network systems.
System Shutdown
Company takes key manufacturing and order processing systems offline to prevent further data destruction.
HHS AI Task Force
Department of Health and Human Services forms a dedicated task force for clinical AI oversight.
Medication Dominance
FDA data confirms medication abortion surpasses surgical procedures as the primary method.
Supreme Court Ruling
SCOTUS maintains access to mifepristone by dismissing a challenge to FDA's rules on procedural grounds.
OMB M-24-10
Office of Management and Budget releases guidance for federal agency use of AI.
Executive Order 14110
President Biden issues the first major EO on Safe, Secure, and Trustworthy AI.
Shield Law Expansion
States like MA and NY pass laws protecting telehealth providers mailing pills to ban states.
Pharmacy Certification
FDA updates REMS to allow retail pharmacies to dispense mifepristone upon certification.
Dobbs Decision
U.S. Supreme Court overturns Roe v. Wade, allowing state-level bans.
Mail-Order Authorization
FDA permanently removes the requirement for in-person dispensing, allowing for telehealth and mail delivery.
Protocol Expansion
FDA extends usage window to 10 weeks and reduces required office visits from three to one.
Initial FDA Approval
FDA approves mifepristone for medical termination of pregnancy through seven weeks.
Medication abortion now accounts for the majority of pregnancy terminations in the United States, driven by the expansion of telehealth and mail-order pharmacy access. This shift has sparked a sophisticated regulatory counter-offensive from opponents targeting FDA-approved protocols and cross-state digital health providers.
New data reveals that the total number of abortions in the United States has remained stable despite a wave of state-level bans and restrictions. This trend is largely driven by the rapid expansion of telehealth services and medication abortion, highlighting a significant shift in how reproductive healthcare is delivered and regulated.
The White House has released a definitive regulatory framework for artificial intelligence, establishing mandatory safety and transparency standards for high-stakes sectors. For healthcare, the move shifts the industry from voluntary guidelines to a rigorous clinical validation and algorithmic accountability regime.
A major scientific consensus has emerged indicating that marijuana does not effectively alleviate anxiety or other mental health conditions. These findings challenge the clinical foundation of medical cannabis programs in 38 states and could trigger significant regulatory shifts.
Stryker Corporation has confirmed significant disruptions to its global manufacturing and order fulfillment systems following a sophisticated cyberattack attributed to the Iranian-linked group Handala. The incident, characterized as a 'wiper' attack, has forced the medical technology leader to take key systems offline, impacting the supply of critical surgical and orthopedic equipment.
The FDA has issued a formal warning letter to Novo Nordisk for failing to properly report serious adverse events, including deaths and strokes, related to its GLP-1 medications. This regulatory escalation coincides with a significant market valuation decline and intensifying competition from compounding pharmacies.
This page surfaces every story mentioning FDA across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where FDA was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |